Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VogenxVOGX +8.38%8 Pretax Margin % is % as of Dec. 2025. GuruFocus rates VOGX with a GF Score™ of 8/100. Among 944 Biotechnology companies, Vogenx ranks worse than 105932.1% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Vogenx's Pre-Tax Income for the
six
months ended in Dec. 2025 was $-1.45 Mil. Vogenx's Revenue for the
six
months ended in Dec. 2025 was $0.00 Mil. Therefore, Vogenx's pretax margin for the quarter that ended in Dec. 2025 was %.
The historical rank and industry rank for Vogenx's Pretax Margin % or its related term are showing as below:
VOGX's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -84.1 * Ranked among companies with meaningful Pretax Margin % only.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Vogenx Pretax Margin % Related Terms
Vogenx Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Vogenx's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vogenx Pretax Margin % Chart
Vogenx Annual Data
Trend
Dec24
Dec25
Pretax Margin %
0.00
0.00
Vogenx Semi-Annual Data
Dec24
Dec25
Pretax Margin %
0.00
0.00
VOGX vs : Pretax Margin % Comparison
For the Biotechnology subindustry, Vogenx's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vogenx Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vogenx's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Vogenx's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vogenx (VOGX) has a Pretax Margin % of % as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Vogenx and its competitors. According to the industry distribution chart, Vogenx ranks #999999 out of 944 companies in the Biotechnology industry.
Is Vogenx's Pretax Margin % too high?
Vogenx's current Pretax Margin % is %. Based on the distribution chart, Vogenx ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vogenx has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Vogenx's Pretax Margin % compare to ?
According to the Biotechnology industry distribution chart, Vogenx ranks #999999 out of 944 companies for Pretax Margin %. This places Vogenx in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Vogenx and its competitors. Vogenx's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vogenx stock overvalued right now?
Vogenx (VOGX) has a current Pretax Margin % of %. The current Pretax Margin % is %. Vogenx's overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Vogenx (VOGX), the current Pretax Margin % is % as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.
8GF Score
Get the complete analysis for VOGX
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VOGX has been successfully added to your 
